Guay David
Department of Experimental and Clinical Pharmacology and Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Drugs. 2003;63(20):2169-84. doi: 10.2165/00003495-200363200-00002.
Accumulating evidence suggests that short-course (</=5 days, </=3 days for azithromycin) antimicrobial therapy may be at least as effective as and, in some cases, may be more effective than traditional longer (10- to 14-day) therapies. In group A beta-haemolytic streptococcal tonsillopharyngitis, short-course therapy with 6 days of amoxicillin, 4-5 days of a variety of cephalosporins and 5 days of clarithromycin modified-release and telithromycin are all reasonable alternatives to traditional 10-day penicillin therapy. Short-course (i.e. 3-day) azithromycin therapy is not recommended because of suboptimal clinical and bacteriological results compared with penicillin therapy, unless the dosage is doubled from 10 to 20 mg/kg/day for all 3 days. In uncomplicated acute suppurative otitis media, single-dose intramuscular ceftriaxone or 3- to 5-day short-course oral antimicrobial therapy should be effective in the majority (>/=80%) of patients. However, more research is clearly needed in the subpopulations of children <2 years of age and in those with unresponsive/recurrent disease, since short-course therapy may not be successful in the majority of these patients. In sinusitis, most short-course therapy data have involved maxillary disease in adult patients. Regimens have included 3 days of azithromycin or cotrimoxazole (trimethoprim/sulfamethoxazole) or 5 days of cefpodoxime, telithromycin, gatifloxacin, gemifloxacin or amoxicillin/clavulanic acid. Preliminary results are encouraging but more study is clearly needed, especially in the paediatric population. In acute bacterial exacerbations of chronic bronchitis, short-course therapy with a variety of cephalosporins, second-generation fluoroquinolones and advanced generation macrolides/azalides/ketolides are all reasonable alternatives to traditional 7- to 14-day therapies. Cost containment in antimicrobial therapy should involve consideration of short-course therapy in the management of the most common types of respiratory tract infections.
越来越多的证据表明,短疗程(≤5天,阿奇霉素为≤3天)抗菌治疗可能至少与传统的长疗程(10至14天)治疗一样有效,在某些情况下可能更有效。在A组β溶血性链球菌性扁桃体咽炎中,6天的阿莫西林、4至5天的各种头孢菌素、5天的克拉霉素缓释制剂和泰利霉素短疗程治疗都是传统10天青霉素治疗的合理替代方案。不推荐短疗程(即3天)阿奇霉素治疗,因为与青霉素治疗相比,其临床和细菌学效果欠佳,除非3天的剂量从10毫克/千克/天加倍至20毫克/千克/天。在无并发症的急性化脓性中耳炎中,单剂量肌内注射头孢曲松或3至5天的短疗程口服抗菌治疗对大多数(≥80%)患者应有效。然而,对于2岁以下儿童亚组以及无反应/复发性疾病患者,显然需要更多研究,因为短疗程治疗在这些患者中的大多数可能不成功。在鼻窦炎中,大多数短疗程治疗数据涉及成年患者的上颌窦疾病。治疗方案包括3天的阿奇霉素或复方新诺明(甲氧苄啶/磺胺甲恶唑)或5天的头孢泊肟、泰利霉素、加替沙星、吉米沙星或阿莫西林/克拉维酸。初步结果令人鼓舞,但显然需要更多研究,尤其是在儿科人群中。在慢性支气管炎急性细菌加重期,各种头孢菌素、第二代氟喹诺酮类药物以及新一代大环内酯类/氮杂内酯类/酮内酯类药物的短疗程治疗都是传统7至14天治疗的合理替代方案。抗菌治疗中的成本控制应在管理最常见类型的呼吸道感染时考虑短疗程治疗。